Within the competitive CDMO market, Richter-Helm has developed into a highly valued partner when it comes to the manufacturing of biopharmaceuticals. Richter-Helm is well recognised by pharmaceutical companies, including Big Pharma, as a professional partner offering flexible CDMO solutions from gene to product, all from one source, including consultancy services. This makes Richter-Helm one of the key players in CDMO business.
Manufacturing Biopharmaceuticals
BackgroundWithin the competitive CDMO market, Richter-Helm has developed into a highly valued partner when it comes to the manufacturing of biopharmaceuticals. Richter-Helm is well recognised by pharmaceutical companies, including Big Pharma, as a professional partner offering flexible CDMO solutions from gene to product, all from one source, including consultancy services. This makes Richter-Helm one of the key players in CDMO business.
Ikxinta – at the forefront of thriving biotech innovation
Sponsored PublicationsIkxinta, a life sciences advisory firm that originated in the Basque Country in 2018, collaborates with scientists, industry innovators, and investors to propel clients in scientific frontiers
SpliceBio has made up a US $216m alliance with Spark Therapeutics
Latest NewsSpliceBio has licenced its intein technlogy to Roche’s gene therapy subsidiary Spark Therapeutics to develop a gene therapy targeting an undisclosed inherited retinal disease.
Antiverse and GlobalBio Inc. extend collaboration
Latest NewsAntiverse Ltd and GlobalBio Inc. have extend their cancer antibody partnership to progress two PD-1 modulators to preclinial development
SOTIO Biotech licenses ADCs from Lonza subsidiary Synaffix BV
Latest NewsSotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
World Health Summit opened in Berlin
Latest NewsOn Sunday, the World Health Summit with more than 300 speakers officially kicked off in Berlin. The three day event focuses on climate change and health, pandemic prevention, and digital technologies.
Synerkine Pharma BV secures EUR 12.1m in Series A extension
Latest NewsDutch Synerkine Pharma BV has closed a Seris A extension financincg at €12.1m to accelerate clinical development of its pain killer SK-01.
AI helps classifying brain tumours during surgery
Latest NewsA method to quickly classify central nervous system (CNS) tumours, combining rapid sequencing and deep-learned AI models, may enable molecular diagnosis in less than 90 minutes, Dutch researchers report.
Test TSKgel UP-SW UHPLC SEC columns risk-free
ProductsTry TSKgel UP-SW columns for SEC analysis of biomolecules risk-free for 30 days
Infrastructure makes the difference
BackgroundA well connected and effective infrastructure, a high density of research and development as well as close networking are of great value, not only to founders. Within the successful healthcare cluster Berlin-Brandenburg, these include numerous technology parks in the region. The parks offer optimal space including state of the art laboratories to start-up and grown-up companies.